Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine
Interventions
BMS-927711 (CGRP Antagonist)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Orlando, Florida + 1 more
Conditions
Migraine Headache
Interventions
Automated Variable Pressure Insufflation
Device
Lead sponsor
Nocira, LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Saint Charles, Missouri
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Not applicable Interventional Results available

STOPAIN in the Treatment of a Single Migraine Attack

NCT01687101
Conditions
Migraine, Headache
Interventions
STOPAIN topical gel
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Conditions
Migraine Headache
Interventions
Argus Migraine Treatment device
Device
Lead sponsor
The San Francisco Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Conditions
Chronic Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Newport Beach, California • Santa Monica, California • Hartford, Connecticut + 7 more
Conditions
Migraine
Interventions
Eletriptan
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
16
States / cities
Irvine, California • Newport Beach, California • San Francisco, California + 13 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

NCT04645953
Conditions
Cyclic Vomiting Syndrome
Interventions
3mg AZ-010, 1mg AZ010, Staccato Placebo
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Lancaster, California • Los Angeles, California • San Diego, California + 14 more
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Conditions
Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Conditions
Chronic Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lagrangeville, New York
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Conditions
Acute Migraine
Interventions
Elismetrep (K-304) Dose Level 1, Elismetrep (K-304) Dose level 2, Elismetrep (K-304) Dose level 3, Elismetrep (K-304) Dose level 4, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Conditions
Migraine
Interventions
Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose, Stage 2: Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
North Miami, Florida
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 76 Years
Enrollment
1,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
177
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more
Conditions
Migraines
Interventions
Ketorolac, Sumatriptan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Completed Phase 4 Interventional Results available

Trial of Comprehensive Migraine Intervention

NCT01071317
Conditions
Migraine
Interventions
Naproxen, Sumatriptan, Migraine education, Reenforcement of diagnosis, Typical care
Drug · Behavioral · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Conditions
Migraine With and Without Aura
Interventions
Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Conditions
Migraine
Interventions
BGG492, Sumatriptan, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Glendale, California • Paramount, California